nasdaq:cnce
|
73234
|
Apr 21st, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 20th, 2024 11:14PM
|
Apr 20th, 2024 11:14PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 20th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 19th, 2024 11:11PM
|
Apr 20th, 2024 04:47PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 19th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 18th, 2024 11:18PM
|
Apr 18th, 2024 11:18PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 18th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 17th, 2024 11:18PM
|
Apr 18th, 2024 06:07PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 17th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 16th, 2024 11:08PM
|
Apr 17th, 2024 02:31PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 16th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 15th, 2024 11:03PM
|
Apr 16th, 2024 10:47AM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 15th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 14th, 2024 11:00PM
|
Apr 15th, 2024 04:29PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 14th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 13th, 2024 10:49PM
|
Apr 13th, 2024 10:49PM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 13th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 12th, 2024 10:40PM
|
Apr 13th, 2024 11:15AM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cnce
|
73234
|
Apr 12th, 2024 12:00AM
|
Concert Pharmaceuticals, Inc.
|
5.6K
|
38.00
|
Open
|
|
Apr 11th, 2024 10:44PM
|
Apr 12th, 2024 08:10AM
|
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
|
Open
|
|
Open
|
65 Hayden Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
Concert Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|